Please assess the completion status of the following clinical trial:

Trial Title: Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive)~* Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP~* Pubertal-type LH response following an abbreviated GnRHa stimulation test before treatment initiation~* Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males~* Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year~Exclusion Criteria:~* Gonadotropin-independent (peripheral) precocious puberty~* Prior or current GnRH treatment for CPP~* Prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1)~* Diagnosis of short stature (ie, 2.25 standard deviations (SD) below the mean height for age)~* Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions~* Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Assigned Intervention (Type: EXPERIMENTAL): Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).